Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

Renier J. Brentjens, MD, PhD
Published Online: Thursday, April 24, 2014
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Brentjens says he is confident that CAR-modified T cell technology will have utility in a far wider array of cancers than just B-cell acute lymphoblastic leukemia (ALL) as researchers and physicians learn more about the immune system, tumor immunology, and target antigens.​

Research is being conducted looking at different receptors for different cancers including acute myeloid leukemia and ovarian cancer.

The answer as to whether this technology has a wider application than just B-cell ALL will be known not after one round of clinical trials, Brentjens says, but as it is adapted to be more specific to tumors and better able to kill tumors.

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer Congress®
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
More Reading
$auto_registration$